Skip to main content

Market Overview

Recap: Bausch Health Q4 Earnings



Shares of Bausch Health Cos (NYSE:BHC) decreased 0.3% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 18.75% year over year to $1.33, which beat the estimate of $1.12.

Revenue of $2,213,000,000 declined by 0.49% year over year, which beat the estimate of $2,170,000,000.

Looking Ahead

The upcoming fiscal year's revenue expected to be between $8,600,000,000 and $8,800,000,000.

Details Of The Call

Date: Feb 24, 2021

Time: 08:00 AM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $32.50

52-week low: $11.15

Price action over last quarter: Up 87.39%

Company Overview

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in four segments: Bausch+Lomb and international (55% of revenue), Salix pharmaceuticals (25%), ortho dermatology (6%), and diversified products (14%), and approximately 13% of revenue is attributable to non-U.S. markets. Bausch is the market leader in consumer visioncare in India and China, and the fourth- largest visioncare company by sales in the United States.


Related Articles (BHC)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at